Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw

Source: George S. Mack of The Life Sciences Report  (02/10/2016)
Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw
Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview, the former big pharma researcher details four growth names that could follow in the footsteps of previous winners. read more >

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell

Source: George S. Mack of The Life Sciences Report  (02/03/2016)
Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Canada encompasses healthcare-related businesses that are generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios: He knows both spheres, and as a hedge fund and mutual fund manager he has made a specialty in acquisitions of cash-generating healthcare companies. read more >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase

Source: Tracy Salcedo of The Life Sciences Report  (01/27/2016)
The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. read more >

Rick Mills: How to Profit from the Demands of a Growing World Population

Source: JT Long of The Gold Report  (01/21/2016)
Rick Mills: How to Profit from the Demands of a Growing World Population
As the world prepares to house, feed and care for 9.7 billion people, Ahead of the Herd founder Rick Mills is looking for the companies that will profit from the silent tsunami of demand creeping up on resource and healthcare providers. read more >

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News

Source: George S. Mack of The Life Sciences Report  (01/20/2016)
The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. read more >

A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe

Source: Staff of The Life Sciences Report  (01/13/2016)
A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe
Canadian healthcare stocks offer a windbreak for biotech investors in a turbulent market, especially if they select a diversified basket across the various sectors, says Euro Pacific Canada's Doug Loe. read more >

Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment

Source: Tracy Salcedo of The Life Sciences Report  (01/06/2016)
Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. In this article, The Life Sciences Report explores the possibilities of new intracellular immunotherapeutic technologies as cures for diseases like cancer—and the prospects for companies advancing these technologies—with three biotech investment experts. read more >
Expert Investing Ideas

"The Neutrolin platform positions CRMD particularly well going forward."

The Life Sciences Interview with Ram Selvaraju


"CYP has the only truly sustainable production platform for MSCs."

The Life Sciences Interview with Ram Selvaraju


"HLTH is now getting to levels we think are very attractive."

The Life Sciences Report Interview with Bruce Campbell


"MSB continues to make good pipeline progress."

–Katherine Genis, Edison Investment Research


"HLTH's reiteration of FY16 guidance is a strong positive."

–Russell Stanley, Mackie Research Capital


"RP had successful proof of concept with RCH-01 with restoring hair."

The Life Sciences Report Interview with Alan Leong


Biotech Watchlist 2016
NASDAQ Biotech ARCA Pharmaceutical
Sorrento_TLSR_HP
Management Q&A: View from the Top

CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report  (02/11/2016)
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc., says CEO Randy Milby, is developing a platform that has shown impressive results in preventing serious bloodstream infections. read more >
Management Q&A: View from the Top

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

Managment Q&A: View from the Top
Source: Peter Byrne of The Life Sciences Report  (02/03/2016)
Stewart Washer
In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. read more >
Management Q&A: View from the Top

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report  (01/27/2016)
Leo Ehrlich
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. read more >